| Name | Title | Contact Details |
|---|
Apps that work seamlessly together to create integrated, multichannel programs that empower people to take a dramatically more active role in improving health. Beyond members and patients, this is healthcare IT that helps doctors, providers, health plan administrators and medical device manufacturers. Not to mention Medicare Star Ratings.
Singulex is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.